
This article investigates the use of guideline-directed medical therapies (GDMT) and associated outcomes in obese (body mass index, BMI≥30 kg/m2) vs. non‐obese patients with heart failure with reduced ejection fraction (HFrEF). 16116 patients from the Swedish HF Registry were included, of which 24% were obese. Obesity was independently associated with more likely use of each treatment, triple combination therapy, and the achievement of target dose (TD). Multivariable Cox regressions showed the use of RASi/ARNi and of beta‐blockers being independently associated with a lower risk of all-cause/cardiovascular death (CVD) regardless of obesity, although a lower risk of CVD when considering competing risks was observed in obese vs. non-obese patients when considering competing risk. Obesity was more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limit GDMT implementation.
Like
Save
Share